Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Nachrichtenquelle: globenewswire
12.08.2020, 17:45  |  113   |   |   

Half-Year Review of Inventiva’s Liquidity Contract with
Kepler Cheuvreux
                         
Daix (France), August 12, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of June 30, 2020:

  • Cash: € 995,433.00
  • Number of shares: 14,361

At the last half-year report as of December 31, 2019, the following resources were available in the liquidity account:

  • Cash: € 260,756.07
  • Number of shares: 66,839

When the contract was initially implemented, the following resources were included in the liquidity account:

  • Cash: € 163,510.42
  • Number of shares: 34,063


About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.

Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. A Phase I/II clinical trial in children with MPS VI is currently under preparation following the release of positive results of the Phase IIa clinical trial in adult MPS VI patients at the end of 2019.

Seite 1 von 3
Inventiva Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Half-Year Review of Inventiva’s Liquidity Contract withKepler Cheuvreux                           Daix (France), August 12, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of …

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Diskussionen zu den Werten

ZeitTitel
12.10.20